Mark A. Wilson - 21 Nov 2025 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Reporting relationship: Chief Legal Officer
Issuer ticker: NKTR
Reported as of: 21 Nov 2025
Net transaction value: -$34,196
SEC form: 4
Accepted by SEC: 25 Nov 2025, 20:29:54 UTC
Prior SEC filing: 21 Aug 2025
Next SEC filing: 15 Jan 2026
Source filing: View source filing
Reporting owner signature: Mark A. Wilson

Key filing fact

Mark A. Wilson filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 25 Nov 2025.

Key facts

This page summarizes Mark A. Wilson's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Nov 2025, 20:29.

Change

Previous filing in this sequence was filed on 21 Aug 2025.
Current net transaction value: -$34,196.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808356 Primary reporting owner

Wilson Mark Andrew

Relationship: Chief Legal Officer
Address: C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO
Signature: Mark A. Wilson
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTR transaction

Common Stock

Award

Transaction value: $0
Shares: +1,903
Change %: +9.4%
Price: $0.000000
Shares after: 22,215
Date: 21 Nov 2025
Ownership: Direct
Footnotes: F1, F2, F3

NKTR transaction

Common Stock

Sale

Transaction value: $34,196
Shares: -630
Change %: -2.8%
Price: $54.28
Shares after: 21,585
Date: 25 Nov 2025
Ownership: Direct
Footnotes: F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NKTR transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +3,400
Change %
Price: $0.000000
Shares after: 3,400
Date: 21 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,400
Exercise price: $281.25
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant.

Footnote F2

The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025.

Footnote F3

This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).

Footnote F4

Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

Footnote F5

This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Footnote F6

These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant.

Footnote F7

The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025.